Livzon Pharmaceutical Group Inc. (HKG: 1513)

Livzon Pharmaceutical Group Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Jan 1, 2022	Jan 1, 2021	Jan 1, 2020
Operating Revenue	11,752	12,326	12,524	11,928	10,463	9,317
Other Revenue	104.45	104.45	105.89	135.88	57.34	67.58
Revenue	11,857	12,430	12,630	12,064	10,520	9,385
Revenue Growth (YoY)	-7.34%	-1.58%	4.69%	14.67%	12.10%	5.91%
Cost of Revenue	4,395	4,772	4,577	4,309	3,744	3,442
Gross Profit	7,462	7,658	8,053	7,754	6,777	5,942
Selling, General & Admin	3,882	4,255	4,545	4,548	3,740	3,723
Research & Development	1,083	1,335	1,427	1,146	884.1	732.89
Other Operating Expenses	149.01	133.07	143.97	135.87	122.94	107.44
Operating Expenses	5,110	5,736	6,121	5,837	4,747	4,569
Operating Income	2,352	1,921	1,932	1,917	2,029	1,374
Interest Expense	-95.67	-102.09	-97.55	-84	-25.31	-7.26
Interest & Investment Income	279.25	429.98	359.25	251.81	323.19	226.43
Currency Exchange Gain (Loss)	10.23	10.23	56.68	-4.28	-41.56	5.38
Other Non Operating Income (Expenses)	-29.39	-4.42	-6.37	-4.01	-5.89	-2.64
EBT Excluding Unusual Items	2,517	2,255	2,244	2,077	2,280	1,596
Gain (Loss) on Sale of Investments	10.84	-25.65	-75.27	-23.03	8.81	-18.27
Gain (Loss) on Sale of Assets	-0.34	-0.17	0.86	7.03	-1.07	0.46
Asset Writedown	45.06	-2.43	-13.99	-6.15	-6.9	0.99
Other Unusual Items	143.2	155.76	174.68	191.12	208.76	148.84
Pretax Income	2,715	2,383	2,331	2,246	2,489	1,728
Income Tax Expense	496.24	485.07	374.97	293.59	358.11	265.96
Earnings From Continuing Operations	2,219	1,898	1,956	1,952	2,131	1,462
Minority Interest in Earnings	-194.34	56.05	-46.17	-176.42	-416.42	-158.7
Net Income	2,025	1,954	1,909	1,776	1,715	1,303
Net Income to Common	2,025	1,954	1,909	1,776	1,715	1,303
Net Income Growth	1.03%	2.32%	7.53%	3.54%	31.63%	20.39%
Shares Outstanding (Basic)	924	929	935	935	936	935
Shares Outstanding (Diluted)	925	931	936	936	939	935
Shares Change (YoY)	-0.74%	-0.56%	-0.04%	-0.25%	0.41%	0.20%
EPS (Basic)	2.19	2.10	2.04	1.90	1.83	1.39
EPS (Diluted)	2.19	2.10	2.04	1.90	1.83	1.39
EPS Growth	1.83%	2.94%	7.47%	3.73%	31.65%	19.83%
Free Cash Flow	2,673	2,428	1,833	593.23	1,514	1,369
Free Cash Flow Per Share	2.89	2.61	1.96	0.63	1.61	1.46
Dividend Per Share	1.350	1.350	1.600	1.300	1.250	1.150
Dividend Growth	-15.63%	-15.63%	23.08%	4.00%	8.70%	24.58%
Gross Margin	62.94%	61.61%	63.76%	64.28%	64.41%	63.32%
Operating Margin	19.84%	15.46%	15.30%	15.89%	19.29%	14.64%
Profit Margin	17.08%	15.72%	15.12%	14.72%	16.30%	13.88%
Free Cash Flow Margin	22.55%	19.54%	14.51%	4.92%	14.39%	14.59%
EBITDA	3,300	2,733	2,563	2,342	2,421	1,758
EBITDA Margin	27.83%	21.99%	20.29%	19.41%	23.01%	18.73%
D&A For EBITDA	947.5	811.67	630.56	425.02	391.69	384.61
EBIT	2,352	1,921	1,932	1,917	2,029	1,374
EBIT Margin	19.84%	15.46%	15.30%	15.89%	19.29%	14.64%
Effective Tax Rate	18.27%	20.36%	16.09%	13.07%	14.39%	15.40%

Source: S&P Capital IQ. Standard template. Financial Sources.